<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1684-1824</journal-id>
<journal-title><![CDATA[Revista Médica Electrónica]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Med.Electrón.]]></abbrev-journal-title>
<issn>1684-1824</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Matanzas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1684-18242024000100061</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La insuficiencia cardiaca con fracción de eyección preservada: diagnóstico y tratamiento médico actual]]></article-title>
<article-title xml:lang="en"><![CDATA[Heart failure with preserved ejection fraction: diagnosis and current medical treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo-Rubido]]></surname>
<given-names><![CDATA[Alfredo Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo-Bruce]]></surname>
<given-names><![CDATA[Alfredo Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Policlínico Comunitario Docente Joaquín de Agüero y Agüero  ]]></institution>
<addr-line><![CDATA[ Camagüey]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Clínico Quirúrgico Docente Amalia Simoni  ]]></institution>
<addr-line><![CDATA[ Camagüey]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>46</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1684-18242024000100061&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1684-18242024000100061&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1684-18242024000100061&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La insuficiencia cardiaca es una de las principales causas de mortalidad a nivel mundial. En la actualidad se ha observado una tendencia a la estabilización e incluso a la disminución de la incidencia. Sin embargo, la insuficiencia cardiaca con fracción de eyección preservada continúa elevando su incidencia, por lo que se realiza esta investigación con el objetivo de actualizar el diagnóstico y tratamiento de esta entidad, acorde a la tendencia actual. Se realizó una revisión bibliográfica de publicaciones científicas de los últimos cinco años, disponibles en bases de datos y repositorios como PubMed, SciELO, Elseiver y otras bibliotecas virtuales. De la misma, se logró actualizar la metodología diagnóstica de esta entidad, utilizando las manifestaciones clínicas, junto a los datos obtenidos en la ecocardiografía, haciendo hincapié en sus diferencias con la disfunción diastólica, junto a la aplicación de diferentes scores para ratificar el diagnóstico. Así mismo, en la actualidad, se ha propuesto el uso de los inhibidores del cotransportador 2 de sodio-glucosa como droga de primera línea, unida a los antagonistas de la aldosterona, el uso de los inhibidores de la angiotensina y el neprilysin, además del tratamiento de comorbilidades y síntomas acompañantes. Se puede concluir que la insuficiencia cardiaca con fracción de eyección preservada, cuenta con métodos diagnósticos y terapéuticos satisfactorios.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Heart failure is one of the main causes of mortality worldwide. Currently, a trend towards stabilization and even a decrease in incidence has been observed. However, heart failure with preserved ejection fraction continues to increase its incidence, which is why this research is carried out with the aim of updating the diagnosis and treatment of this entity, according to the current trend. A bibliographic review of scientific publications from the last five years available in databases and repositories such as PubMed, SciELO, Elsevier, and other virtual libraries was carried out. From it, it was possible to update the diagnostic methodology of this entity, using the clinical manifestations, together with the data obtained in echocardiography, emphasizing its differences with diastolic dysfunction, together with the application of different scores to ratify the diagnosis. Likewise, at present, the use of sodium-glucose co-transporter 2 inhibitors has been proposed as first-line drug, together with aldosterone antagonists, the use of angiotensin inhibitors and neprilysin, in addition to the treatment of comorbidities and accompanying symptoms. It can be concluded that heart failure with preserved ejection fraction has satisfactory diagnostic and therapeutic methods.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[insuficiencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[fracción de eyección ventricular]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="en"><![CDATA[heart failure]]></kwd>
<kwd lng="en"><![CDATA[ventricular ejection fraction]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2022</year>
<volume>79</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>421</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[AJS]]></given-names>
</name>
<name>
<surname><![CDATA[Tsutsui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2021</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>387-413</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsao]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Aday]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Almarzooq]]></surname>
<given-names><![CDATA[ZI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics-2023 update: a report from the American Heart Association]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2023</year>
<volume>147</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>621</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Dirección de Registros Médicos y Estadísticas de Salud</collab>
<source><![CDATA[Anuario Estadístico de Salud 2021]]></source>
<year>2022</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kittleson]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Panjrath]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Amancherla]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2023</year>
<volume>81</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1835-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abovich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matasic]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention]]></article-title>
<source><![CDATA[Am J Prev Cardiol]]></source>
<year>2023</year>
<volume>15</volume>
<page-range>100527</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 AHA/ACC/HFSA guideline for the management of heart failure]]></article-title>
<source><![CDATA[J Card Fail]]></source>
<year>2022</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>167</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pieske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tschope]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[de Boer]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2019</year>
<volume>40</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>3297-317</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ivey]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positive Predictive Value of International Classification of Diseases, Ninth Revision, Clinical Modification, and International Classification of Diseases, Tenth Revision, Clinical Modification, Codes for Identification of Congenital Heart Defects]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2023</year>
<volume>12</volume>
<numero>16</numero>
<issue>16</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redfield]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Borlaug]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart failure with preserved ejection fraction: A review]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2023</year>
<volume>329</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>827-38</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pandey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Neeland]]></surname>
<given-names><![CDATA[IJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and prognostic considerations for use of natriuretic peptides in obese patients with heart failure]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2020</year>
<volume>63</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>649-55</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selvaraj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Myhre]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Vaduganathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community]]></article-title>
<source><![CDATA[J Am Coll Cardiol HF]]></source>
<year>2020</year>
<volume>8</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>640-53</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanders-van Wijk]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barandiarán Aizpurua]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brunner-La Rocca]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The HFA-PEFF and H2 FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2021</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>838-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koepp]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[YNV]]></given-names>
</name>
<name>
<surname><![CDATA[Obokata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of patients with preclinical heart failure with preserved ejection fraction using the H2FPEF score]]></article-title>
<source><![CDATA[Nat Cardiovasc Res]]></source>
<year>2022</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-66</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation the value of H2FPEF score and HFA-PEFF step E score in the diagnosis of heart failure with preserved ejection fraction]]></article-title>
<source><![CDATA[Acta Cardiol]]></source>
<year>2023</year>
<volume>78</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>790-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the inflammatory myopathy population]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2023</year>
<volume>25</volume>
<numero>141</numero>
<issue>141</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Heart Failure with Preserved Ejection Fraction-A Metabolic Disease?]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>389</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1145-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fácila Rubio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lozano-Granero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal-Pérez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas tecnologías para el diagnóstico, tratamiento y seguimiento de las enfermedades cardiovasculares]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2024</year>
<volume>77</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>88-96</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hominal]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global Variations in Heart Failure Etiology, Management, and Outcomes]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2023</year>
<volume>329</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>1650-61</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Coronel]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Echazarreta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Registro Argentino de insuficiencia cardíaca con fracción de eyección preservada: ArFey-Preser: Comité de Insuficiencia Cardíaca e Hipertensión Pulmonar de la Federación Argentina de Cardiología]]></article-title>
<source><![CDATA[Rev Fed Arg Cardiol]]></source>
<year>2023</year>
<volume>52</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>97-103</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz Quintero]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento actual de la insuficiencia cardíaca con fracción de eyección preservada]]></article-title>
<source><![CDATA[Diabetes práctica]]></source>
<year>2023</year>
<volume>14</volume>
<numero>^sSuppl 4</numero>
<issue>^sSuppl 4</issue>
<supplement>Suppl 4</supplement>
<page-range>1-46</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso de Insuficiencia Cardíaca 2022]]></article-title>
<collab>Sociedad Argentina de Cardiología</collab>
<source><![CDATA[Rev Argent Cardiol]]></source>
<year>2023</year>
<volume>91</volume>
<numero>^sSuppl 2</numero>
<issue>^sSuppl 2</issue>
<supplement>Suppl 2</supplement>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Psotka]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fiuzat]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium]]></article-title>
<source><![CDATA[J Am Coll Cardiol HF]]></source>
<year>2020</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>961-72</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blum]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
<name>
<surname><![CDATA[Jaarsma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palliative Care in Heart Failure Guidelines-A Comparison of the 2021 ESC and the 2022 AHA/ACC/HFSA Guidelines on Heart Failure]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2023</year>
<volume>25</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1849-55</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speranza Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Avilés Bósquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cadena Barranco]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tercer Consenso Centroamericano y de El Caribe para el manejo de la Insuficiencia Cardíaca]]></article-title>
<source><![CDATA[Rev Costarric Cardiol]]></source>
<year>2022</year>
<volume>24</volume>
<numero>^sSuppl 2</numero>
<issue>^sSuppl 2</issue>
<supplement>Suppl 2</supplement>
<page-range>3-39</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tárraga López]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Iruela Martínez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tárraga]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novedades de la insuficiencia cardíaca y los inhibidores del cotransportador de sodio-glucosa 2]]></article-title>
<source><![CDATA[J Health Sci]]></source>
<year>2023</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>144-56</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ikram]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial]]></article-title>
<source><![CDATA[Expert Rev Clin Pharmacol]]></source>
<year>2021</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>523-5</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CSP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2020</year>
<volume>141</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>338-51</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Girerd]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials]]></article-title>
<source><![CDATA[Eur J Heart Fail]]></source>
<year>2023</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>108-13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
